基于影像多组学数据库的无创可视化新方法,揭示乳腺癌肿瘤内异质性表型和治疗靶点
研究背景
研究结果
▌研究设计和队列概述
通过整体增强磁共振成像(DCE-MRI)图像,将肿瘤区域划定为目标区域(ROIs),并提取定量放射学特征,建立了三个独立的放射组学队列。
开发一种用于识别IITH不同亚型的影像学特征标志,来区分发现队列和验证队列中的不同IITH亚型,同时对IITH的预后价值进行评估和验证。
将IITH与基因组肿瘤异质性和细胞形态肿瘤异质性相关联,从多层次的异质性验证以确认IITH的可靠性。
探索高IITH且预后不良患者的分子特征和潜在治疗选择。
图2. 多中心乳腺癌患者队列
(A:数据库纳排流程图;B:三个队列中多维数据的样本大小;C:本研究中三个队列的作用)
▌识别IITH
图3. 肿瘤内影像组学、临床病理特征以及无复发生存和总生存结果
▌IITH预后价值的发现和验证
图4. FUSCC队列的多变量Cox分析显示,高IITH是预后不良的独立预测指标
▌IITH与基因组和病理性ITH的相关性
图5. 肿瘤内影像组学、基因组学与细胞形态学异质性的相关性
▌与IITH相关的基因组、转录组和代谢组的改变
图6. 肿瘤内影像组学异质性高的乳腺癌生物学特征
▌铁死亡是高IITH肿瘤的生物学特征和潜在治疗靶点
图7. 肿瘤内影像组学异质性高的乳腺癌对铁死亡靶向治疗敏感
讨论与思考
参考文献:
[1]Su GH, Xiao Y, You C, et al. Radiogenomic-based multiomic analysis reveals imaging intratumor heterogeneity phenotypes and therapeutic targets. Sci Adv. 2023 Oct 6;9(40):eadf0837.
[2]Yates LR, Gerstung M, Knappskog S, et al. Subclonal diversification of primary breast cancer revealed by multiregion sequencing. Nat Med. 2015 Jul;21(7):751-9.
[3]Barry WT, Kernagis DN, Dressman HK, et al. Intratumor heterogeneity and precision of microarray-based predictors of breast cancer biology and clinical outcome. J Clin Oncol. 2010 May 1;28(13):2198-206.
[4]Roth A, Khattra J, Yap D, et al. PyClone: statistical inference of clonal population structure in cancer. Nat Methods. 2014 Apr;11(4):396-8.
[5]Mroz EA, Rocco JW. MATH, a novel measure of intratumor genetic heterogeneity, is high in poor-outcome classes of head and neck squamous cell carcinoma. Oral Oncol. 2013 Mar;49(3):211-5.
[6]Xue R, Li R, Guo H, et al. Variable Intra-Tumor Genomic Heterogeneity of Multiple Lesions in Patients With Hepatocellular Carcinoma. Gastroenterology. 2016 Apr;150(4):998-1008.
[7]Andor N, Graham TA, Jansen M, et al. Pan-cancer analysis of the extent and consequences of intratumor heterogeneity. Nat Med. 2016 Jan;22(1):105-13.
[8]van Griethuysen JJM, Fedorov A, Parmar C, et al. Computational Radiomics System to Decode the Radiographic Phenotype. Cancer Res. 2017 Nov 1;77(21):e104-e107.
[9]Keenan T, Moy B, Mroz EA, et al. Comparison of the Genomic Landscape Between Primary Breast Cancer in African American Versus White Women and the Association of Racial Differences With Tumor Recurrence. J Clin Oncol. 2015 Nov 1;33(31):3621-7.
[10]Chitalia RD, Rowland J, McDonald ES, et al. Imaging Phenotypes of Breast Cancer Heterogeneity in Preoperative Breast Dynamic Contrast Enhanced Magnetic Resonance Imaging (DCE-MRI) Scans Predict 10-Year Recurrence. Clin Cancer Res. 2020 Feb 15;26(4):862-869.
[11]Aerts HJ, Velazquez ER, Leijenaar RT, et al. Decoding tumour phenotype by noninvasive imaging using a quantitative radiomics approach. Nat Commun. 2014 Jun 3;5:4006.
[12]Jiang L, You C, Xiao Y, et al. Radiogenomic analysis reveals tumor heterogeneity of triple-negative breast cancer. Cell Rep Med. 2022 Jul 19;3(7):100694.
[13]McGranahan N, Swanton C. Clonal Heterogeneity and Tumor Evolution: Past, Present, and the Future. Cell. 2017 Feb 9;168(4):613-628.
[14]Hua X, Zhao W, Pesatori AC, et al. Genetic and epigenetic intratumor heterogeneity impacts prognosis of lung adenocarcinoma. Nat Commun. 2020 May 18;11(1):2459.
[15]Greaves M. Evolutionary determinants of cancer. Cancer Discov. 2015 Aug;5(8):806-20.
[16]Marusyk A, Janiszewska M, Polyak K. Intratumor Heterogeneity: The Rosetta Stone of Therapy Resistance. Cancer Cell. 2020 Apr 13;37(4):471-484.
[17]Lei G, Zhuang L, Gan B. Targeting ferroptosis as a vulnerability in cancer. Nat Rev Cancer. 2022 Jul;22(7):381-396.
[18]Liang C, Zhang X, Yang M, et al. Recent Progress in Ferroptosis Inducers for Cancer Therapy. Adv Mater. 2019 Dec;31(51):e1904197. .
[19]Llabani E, Hicklin RW, Lee HY, et al. Diverse compounds from pleuromutilin lead to a thioredoxin inhibitor and inducer of ferroptosis. Nat Chem. 2019 Jun;11(6):521-532.
*“医学界”力求所发表内容专业、可靠,但不对内容的准确性做出承诺;请相关各方在采用或以此作为决策依据时另行核查。
微信扫码关注该文公众号作者